Quest Diagnostics (DGX) Stock
Leading US clinical laboratory company with extensive scale. Here's the price, business snapshot, and what's worth knowing about Quest Diagnostics in October 2026.
Quest Diagnostics (DGX) is a leading US clinical laboratory services company that provides diagnostic testing, information and services to healthcare providers, hospitals, employers and insurers. Its business is driven by volume of tests, reimbursement rates and specialised, higher-margin diagnostics such as molecular and genomics testing. The company benefits from scale, extensive logistics and long-term contracts but faces competition from other national labs, hospital systems and growing point-of-care testing. Key investor considerations include demand trends for routine and specialised tests, reimbursement and regulatory pressure, and capital investment in automation and new technologies. Quest has historically returned cash via dividends and buybacks, though investors should weigh yield against growth prospects and margin sensitivity. Market cap is about $20.54bn. This summary is for general educational purposes only and is not personalised investment advice; values can fall as well as rise and you should consider your circumstances or speak with a financial adviser.
Why It’s Moving
Quest Diagnostics Faces Reimbursement Headwinds Despite Strong Organic Growth and AI Momentum
- The Centers for Medicare & Medicaid Services announced plans to cut lab testing reimbursement by 15% starting next year, citing years of overpayment to Quest Diagnostics.
- CEO Jim Davis reported that the company is exceeding its prior investor day growth framework, driven largely by organic consumer-health demand and partnerships rather than acquisitions.
- A new study published in JAMA Network Open found that nearly one-third of Lyme-seropositive patients had antibodies to other tick-borne pathogens, highlighting broader testing needs and potential volume opportunities.
Quest Diagnostics Faces Reimbursement Headwinds Despite Strong Organic Growth and AI Momentum
- The Centers for Medicare & Medicaid Services announced plans to cut lab testing reimbursement by 15% starting next year, citing years of overpayment to Quest Diagnostics.
- CEO Jim Davis reported that the company is exceeding its prior investor day growth framework, driven largely by organic consumer-health demand and partnerships rather than acquisitions.
- A new study published in JAMA Network Open found that nearly one-third of Lyme-seropositive patients had antibodies to other tick-borne pathogens, highlighting broader testing needs and potential volume opportunities.
Sixth Month Growth Performance
When is the next earnings date for QUEST DIAGNOSTICS INC (DGX)?
Quest Diagnostics has a confirmed upcoming earnings report scheduled for October 22, 2026, before the market opens. This release will cover the company's third-quarter financial results for the period ending in late September 2026. Investors should monitor this date for official updates on operational performance and guidance.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Quest Diagnostics stock, expecting it to rise to $204.61.
Financial Health
Quest Diagnostics is showing solid revenue and cash flow, indicating a strong financial position overall.
Dividend
Quest Diagnostics has a below-average dividend yield of 1.42%, indicating limited returns from dividends. If you invested $1000, you would be paid $14.20 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Steady testing demand
Routine and chronic‑care testing provides consistent revenue streams, though volumes can shift with public‑health trends and reimbursement changes.
Diagnostic innovation
Growth in molecular and genomic testing and investments in automation may lift margins, but these require capital and carry technological risk.
Market dynamics
Industry consolidation and payer negotiations influence pricing power, so regulatory and competitive shifts can materially affect performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
